VK2735
VK2735 is a GIP receptor agonist in the GLP-1 Agonist class. VK2735 co-activates the GLP-1 and GIP receptors, the same pairing as tirzepatide. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic and brainstem circuits, while GIP receptor activation contributes additional effects on insulin secretion and adipose tissue metabolism that appear to add to weight reduction beyond GLP-1 alone.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Administration Route
- subcutaneous, oral
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Investigational dual agonist of the GLP-1 and GIP receptors in clinical development for obesity and metabolic disease, in both injectable and oral formulations. Not FDA-approved.
Peptide Library's VK2735 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous, oral
- Reconstitution Guide
- —
Science
Mechanism of Action
VK2735 co-activates the GLP-1 and GIP receptors, the same pairing as tirzepatide. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic and brainstem circuits, while GIP receptor activation contributes additional effects on insulin secretion and adipose tissue metabolism that appear to add to weight reduction beyond GLP-1 alone.
Studies
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study
- Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (class-level evidence)
- Tirzepatide for overweight and obesity management (class-level evidence)
- Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? (class-level evidence)
- Cardiovascular effects of tirzepatide (class-level evidence)
Regulatory & research status
VK2735 has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Research status | Investigational; clinical development reported |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
VK2735: frequently asked questions
What is VK2735?
Investigational dual agonist of the GLP-1 and GIP receptors in clinical development for obesity and metabolic disease, in both injectable and oral formulations. Not FDA-approved.
How does VK2735 work?
VK2735 co-activates the GLP-1 and GIP receptors, the same pairing as tirzepatide. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic and brainstem circuits, while GIP receptor activation contributes additional effects on insulin secretion and adipose tissue metabolism that appear to add to weight reduction beyond GLP-1 alone.
Is VK2735 FDA approved?
No. VK2735 is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What peptides are similar to VK2735?
Compounds most often compared with VK2735 include Tirzepatide, Ecnoglutide, Efpeglenatide and Semaglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study — Obesity (Silver Spring), 2026External reference
- Class-level evidence — Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? — Diabetes Care, 2024External reference
- Class-level evidence — Tirzepatide for overweight and obesity management — Expert Opin Pharmacother, 2025External reference
- Class-level evidence — Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? — Diabetes Obes Metab, 2025External reference
- Class-level evidence — Cardiovascular effects of tirzepatide — J Endocrinol, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This VK2735 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track VK2735 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →